Filings Flow: Why Par Investment Partners Lp Reported Big Champions Oncology, Inc Position?

Filings Flow: Why Par Investment Partners Lp Reported Big Champions Oncology, Inc Position?

The New Par Investment Partners Lp Holding in Champions Oncology, Inc

Par Investment Partners Lp filed with the SEC SC 13D/A form for Champions Oncology, Inc. The form can be accessed here: 000119312516751759. As reported in Par Investment Partners Lp’s form, the filler as of late owns 4.0% or 444,005 shares of the Health Care–company.

Champions Oncology, Inc stake is a new one for the and it was filed because of activity on September 9, 2016. We feel this shows Par Investment Partners Lp’s positive view for the stock.

Business Profile

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

The stock decreased 11.11% or $0.2 on October 28, hitting $1.6. About 40,162 shares traded hands. Champions Oncology Inc (NASDAQ:CSBR) has declined 50.00% since March 28, 2016 and is downtrending. It has underperformed by 54.71% the S&P500.

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company has a market cap of $19.03 million. The Firm has two business divisions: Personalized Oncology Solutions and Translational Oncology Solutions (TOS). It currently has negative earnings. The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

More notable recent Champions Oncology Inc (NASDAQ:CSBR) news were published by: Prnewswire.com which released: “Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year …” on September 09, 2016, also Prnewswire.com with their article: “Champions Oncology to Announce Year-End 2016 Financial Results on Thursday …” published on July 25, 2016, Prnewswire.com published: “Champions Oncology Announces Initiation of Prospective Correlative Trial in …” on January 21, 2016. More interesting news about Champions Oncology Inc (NASDAQ:CSBR) were released by: Prnewswire.com and their article: “Champions Oncology Announces $14 Million Capital Raise” published on March 12, 2015 as well as Streetinsider.com‘s news article titled: “Form 4 CHAMPIONS ONCOLOGY, INC. For: Oct 21 Filed by: Morris Ronnie” with publication date: October 24, 2016.

According to Zacks Investment Research, “Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.”

CSBR Company Profile

Champions Oncology, Inc., incorporated on June 4, 1985, is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Firm has two business divisions: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The Company’s POS business provides physicians and patients information to help guide the development of personalized treatment plans. The Company’s TOS business provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The Company’s TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from individual patients that it has preserved for future implantation in mice, along with the patient data and molecular information associated with these tumors, are referred to as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank. As of April 30, 2016, the Company has approximately 800 PDX Models in its TumorBank. It implants tumors in mice to provide pharmaceutical and biotechnology companies the opportunity to test oncology compounds on multiple tumors to test efficacy and simulate the results of human clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment